Pharma could be the best parking spot for your money if the market keeps trending downward.
Shares of the New York City-based pharmaceutical giant are rising on Monday.
The cancer drug market is expected to grow from a surveyed total value of $78 billion in 2015 to over $110 billion by 2020.
Biotech ETFs could mitigate risk amid the sector's volatility, and names such as Exelixis, ANI Pharmaceuticals and Progenics hold promise.
Let's check our indicators.
Pfizer may have poked the bear.
Shorts aren't shying away from the cannabis industry even after a series of squeezes.
Eli Lilly's excellent earnings weren't excellent enough.
LLY's stock slide after earnings might present a buying opportunity.
The giant drugmaker raised its profit guidance for all of 2018 after its third-quarter results beat expectations.